You just read:

Braeburn Announces FDA Acceptance with Priority Review of New Drug Application for CAM2038 Buprenorphine Depot for the Treatment of Opioid Use Disorder

News provided by

Braeburn Pharmaceuticals, Inc.

Sep 18, 2017, 02:00 ET